Skip to content

US · EVGN · BIOTECHNOLOGY

Evogene Ltd. (EVGN) intrinsic value and stock valuation

$0.32as of 2026-11-21 · Mkt cap 5.44M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Evogene Ltd. DCF and intrinsic value

InvestorsCraft values EVGN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EVGN’s statements →

Evogene Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Rehovot, HM 7638517 evogene.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.85M+29.9% 5y CAGRd
20112025
Net income
-$-8.48M
20112025
Free cash flow
-$-13.64M
20112025
Total equity
$12M-26.8% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.85M$5.58M$2.98M$1.68M$930K
Operating income-$-14.03M-$-18.8M-$-22.23M-$-26.94M-$-30.95M
Net income-$-8.48M-$-16.48M-$-23.88M-$-26.64M-$-27.79M
EPSd-$-1.08M-$-2.89M-$-5.23M-$-6.47M-$-677.64K
Operating cash flow-$-13.5M-$-19.7M-$-21.58M-$-23.68M-$-24.84M
Capital expenditure-$-140K-$-630K-$-790K-$-1.17M-$-720K
Free cash flow-$-13.64M-$-20.33M-$-22.36M-$-24.85M-$-25.56M
Total assets$20.1M$39.9M$51.1M$56.1M$76.3M
Total debt$2.2M$12.9M$11.5M$11.9M$2.67M
Net debt-$-10.76M-$-2.43M-$-9.27M-$-17.05M-$-29.66M
Total equity$12M$14.8M$28.7M$34.8M$63.4M
Cash and short-term investments$13M$15.3M$31.1M$35.4M$53.9M
Income statement
20252024202320222021
Revenue$3.85M$5.58M$2.98M$1.68M$930K
Cost of revenue$4.09M$2.38M$1.49M$910K$770K
Gross profit-$-240K$3.2M$1.49M$770K$160K
Research and development expenses$7.99M$12.5M$16.2M$20.8M$21.1M
Selling, general and administrative expenses$5.76M$8.98M$7.53M$10.4M$9.99M
Other expenses$40K$510K$0.00-$-3.5M$0.00
Operating expenses$13.8M$22M$23.7M$27.7M$31.1M
Cost and expenses$17.9M$24.4M$25.2M$28.6M$31.9M
Interest income$2.47M$960K$1.25M$180K$290K
Interest expense$1.89M$120K$170K$240K$400K
Depreciation and amortization$1.14M$1.38M$1.3M$2.58M$2.23M
Ebitda-$-12.2M-$-13.36M-$-20.53M-$-27.01M-$-27.88M
Operating income-$-14.03M-$-18.8M-$-22.23M-$-26.94M-$-30.95M
Total other income/expenses, net$540K$4M$280K-$-2.81M$520K
Income before tax-$-13.5M-$-14.81M-$-21.95M-$-29.75M-$-30.43M
Income tax expense$0.00$10K$20K$90K$10K
Net income-$-8.48M-$-16.48M-$-23.88M-$-26.64M-$-27.79M
Weighted average shares outstanding$7.87M$5.7M$4.57M$4.12M$41M
Weighted average diluted shares outstanding$7.87M$5.7M$4.57M$4.12M$41M
Balance sheet
20252024202320222021
Cash and short-term investments$13M$15.3M$31.1M$35.4M$53.9M
Net receivables$1.38M$1.49M$800K$800K$1.17M
Inventory$210K$1.82M$80K$570K$90K
Total current assets$15.6M$21.6M$34.5M$37.8M$56.9M
Property, plant and equipment, net$2.64M$4.25M$3.44M$4.07M$4.18M
Goodwill and intangible assets$0.00$12.2M$13.2M$14.1M$15.2M
Long-term investments$40K$80K$0.00$0.00$0.00
Total non-current assets$4.42M$18.3M$16.6M$18.4M$19.4M
Total assets$20.1M$39.9M$51.1M$56.1M$76.3M
Accounts payable$640K$1.23M$1.78M$1.04M$1.46M
Short-term debt$720K$11M$1.71M$1.77M$1.95M
Deferred revenue$70K$680K$750K$100K$260K
Total current liabilities$3.44M$18.7M$6.94M$5.62M$6.88M
Long-term debt$1.48M$1.91M$10.7M$11.1M$1.7M
Deferred revenue, non-current$3.07M$4.33M$4.43M$4.67M$4.31M
Total non-current liabilities$4.63M$6.33M$15.5M$15.7M$6M
Capital lease obligations$2.2M$2.5M$1.14M$1.82M$2.67M
Total liabilities$8.07M$25M$22.4M$21.3M$12.9M
Common stock$490K$360K$290K$230K$230K
Retained earnings-$-282.56M-$-274.07M-$-257.59M-$-233.71M-$-207.07M
Accumulated other comprehensive income (loss)$0.00$272.3M$269.4M$261.4M$260.5M
Total equity$12M$14.8M$28.7M$34.8M$63.4M
Total investments$40K$90K$10.3M$6.38M$21.5M
Total debt$2.2M$12.9M$11.5M$11.9M$2.67M
Net debt-$-10.76M-$-2.43M-$-9.27M-$-17.05M-$-29.66M
Cash flow statement
20252024202320222021
Net income-$-14.16M-$-18.05M-$-25.95M-$-29.84M-$-30.45M
Depreciation and amortization$1.14M$2.5M$2.61M$2.58M$2.23M
Stock-based compensation$650K$1.79M$1.88M$1.19M$2.61M
Change in working capital-$-1.25M-$-3.31M-$-400K-$-770K$1.66M
Accounts receivable$1.71M$190K-$-1.45M-$-70K-$-60K
Inventory-$-1.02M-$-1.74M$490K-$-470K-$-90K
Accounts payable-$-260K-$-600K$740K-$-470K$620K
Net cash provided by operating activities-$-13.5M-$-19.7M-$-21.58M-$-23.68M-$-24.84M
Investments in property, plant and equipment-$-140K-$-630K-$-790K-$-1.17M-$-720K
Acquisitions, net$80K$0.00$0.00$0.00$0.00
Net cash used for investing activities$17.7M$9.62M-$-4.54M$13.3M-$-20.44M
Common stock issued$4.28M$120K$8.45M$20K$29.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-6.6M$4.66M$18.2M$9.34M$30.3M
Net change in cash-$-2.35M-$-5.47M-$-8.21M-$-3.35M-$-13.9M
Cash at end of period$13M$15.3M$20.8M$29M$32.3M
Operating cash flow-$-13.5M-$-19.7M-$-21.58M-$-23.68M-$-24.84M
Capital expenditure-$-140K-$-630K-$-790K-$-1.17M-$-720K
Free cash flow-$-13.64M-$-20.33M-$-22.36M-$-24.85M-$-25.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Evogene Ltd.

        Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

        CEO
        Ofer Haviv
        Employees
        52
        Beta
        0.78

        Explore

        Frequently asked questions

        What is the intrinsic value of Evogene Ltd. (EVGN)?

        InvestorsCraft does not currently publish an intrinsic value for EVGN. How the IC value is calculated.

        Is EVGN undervalued?

        InvestorsCraft does not publish an undervaluation signal for EVGN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.